5 medical stocks to watch out for in 2022 -TLX, RHT, CYC, IPD, AVR 

Image Source: © 2021 Kalkine Media


  • The rising population and the rise in health issues are increasing the demand for healthcare products and services.
  • People’s lifestyle is one of the reasons for rising health issues in the present times.
  • TLX, RHT, CYC, IPD, AVR are five stocks from the healthcare space that can be explored in 2022.

It would not be an exaggeration to say that the rise in population is directly proportional to the demand for medical services and products. As per a report, recently published by the Australian Bureau of Statistics, people with age group 20 years to 49 years made up 44% of the collective capital city population, compared with 36% of the population in the remaining parts of Australia. People with age 50 years & beyond make up 32% of the people in cities which is 39% in the rest of Australia.

With the increase in the number of health issues as a result of people’s lifestyle and age, there is an increase in the demand for medical equipment and hospitals to treat these health issues.

In this article, we would look at a few healthcare players who made significant progress lately and we feel these stocks can be further explored in 2022.

Telix Pharmaceuticals Limited (ASX:TLX)

Telix Pharmaceuticals is a biopharmaceutical firm that focuses on developing diagnostic and therapeutic products with the help of  Molecularly Targeted Radiation.

On 2 November 2021, TLX announced that its prostate cancer imaging product Illuccix® got approved by the Australian Therapeutic Goods Administration. This product is a positron emission tomography agent which supports diagnostic imaging of men suffering from prostate cancer.

Soon, the Company aims the commercial rollout of Illuccix. It would establish its leading presence in the urologic oncology domain. Besides, it would go for regulatory filing of kidney cancer imaging products.

TLX closed 1.393% lower at AU$7.080 per share on 23 November 2021. 

ALSO READ: Telix (ASX:TLX) trades strong on signing distribution deal with Radius

Resonance Health Ltd (ASX:RHT)

Resonance Health is an Australian healthcare technology & services business. On 23 November 2021, RHT announced that it has filed two further Australian provisional patent applications including the application of novel Antisense Oligonucleotides (ASOs) for treating human diseases.

Two other provisional patent applications have been filed, comprising:

  • Method for Treating Cyclophilin B Linked Diseases.
  • Method for Treating Cyclophilin D Linked Diseases.

On 12 November 2021, Resonance Health entered into Patient Access to FerriSmart® Letter of Agreement with WHO related to Cyprus-based, Thalassaemia International Federation.  Under this Letter of Agreement,  Thalassaemia International Federation would deploy 500 FerriSmart® vouchers across low-and-middle-income nations in Asia, West Pacific, and Europe. RHT would provide 500 FerriSmart® vouchers.

The stock closed 9.999% higher at AU$0.110 per share on Tuesday.

ALSO READ: 3 Medical imaging stocks for 2022 - TLX, RHT, CYC

Cyclopharm Limited (ASX:CYC)

Cyclopharm Limited is a leading diagnostic lung imaging firm. Its lead nuclear medicine product Technegas® is available in 60 nations & has further opportunities to grow in the US. Technegas™ is the best functional lung ventilation agent.

In the recent Bell Potter Healthcare Conference presentation, the Company highlighted positive cash flow from sales of Technegas across 60 nations with further revenue improving from third party distribution.

The Company has a strong balance sheet to fund the growth strategy.

CYC ended Tuesday’s session at AU$1.925 per share.

ImpediMed Limited (ASX:IPD)

Medical software technology firm ImpediMed recently completed its capital raising. It raised AU$35 million through placement. The SPP was increased to AU$7.5 million. The funds raised through placement and SPP would be used by the Company to support product, data, and software improvements, development, and commercialisation of renal failure application along with general working capital use.

Copyright © 2021 Kalkine Media

Other than this, the Company announced that AstraZeneca extended its agreement for the Stage IIb trial which is using SOZO® to evaluate fluid volume in patients with heart failure & chronic kidney disease, by 3 months. Further, AstraZeneca also boosted the number of SOZO devices needed by 36. Thus, taking the total count in the trial to more than 210.

Meanwhile, the stock closed a tad lower at AU$0.175 per share on  23 November 2021.

ALSO READ: ImpediMed (ASX:IPD) signs Corporate Oncology deal with Icon Group

Anteris Technologies Ltd (ASX:AVR)

Anteris Technologies is a structural heart business that offers clinically better & durable solutions by means of improved science as well as design. It aims on developing next-generation technologies that support healthcare professionals make life-changing results for patients.

On 22 November 2021, the Company reported that it implanted five TAVR patients during the week of 14 November 2021 in a first-in-human study to evaluate the DurAVR™ THV system for curing serious aortic stenosis.

The transcatheter aortic valve replacement procedures for all 5 patients were positive and there were no complications. A further five patients are scheduled for treatment in Q1 2022 to complete the study.

Anteris closed at AU$10.000 per share on Tuesday.

Bottom Line:

The above-mentioned companies have made significant progress in Q2 2021. Thus, the stocks of these businesses can be explored while looking for companies from the healthcare space.



The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and